

INFORMATION TO USERS

This dissertation was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted.

The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction.

1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity.
2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You will find a good image of the page in the adjacent frame.
3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete.
4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation. Silver prints of "photographs" may be ordered at additional charge by writing the Order Department, giving the catalog number, title, author and specific pages you wish reproduced.

University Microfilms

300 North Zeeb Road
Ann Arbor, Michigan 48106
A Xerox Education Company

72-31,878

O'DORISIO, Mary Susanna, 1944-
EFFECTS OF ESTRADIOL-17 β ON THE SYNTHESIS OF NAD
AND NADP IN THE RAT UTERUS.

The University of Nebraska, Ph.D., 1972
Biochemistry

University Microfilms, A XEROX Company, Ann Arbor, Michigan

© 1972

MARY SUSANNA O'DORISIO

ALL RIGHTS RESERVED

THIS DISSERTATION HAS BEEN MICROFILMED EXACTLY AS RECEIVED

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

EFFECTS OF ESTRADIOL-17 β ON THE SYNTHESIS OF NAD
AND NADP IN THE RAT UTERUS

by

Mary Sue O'Dorisio

A DISSERTATION

Presented to the Faculty of
The Graduate College in the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Doctor of Philosophy
Department of Biochemistry

Under the Supervision of Professor Kenneth L. Barker

Omaha, Nebraska

June, 1972

TITLE

Effects of Estradiol-17 β on the Synthesis of NAD and NADP

in the Rat Uterus

BY

Mary Sue O'Dorisio

APPROVED

DATE

Kenneth L. Barker, Ph.D.

June 26, 1972

William R. Ruegamer, Ph.D.

June 26, 1972

Theodore Mahowald, Ph.D.

June 26, 1972

John F. Hofert, Ph.D.

June 26, 1972

Norman G. Miller, Ph.D.

June 26, 1972

SUPERVISORY COMMITTEE

GRADUATE COLLEGE

UNIVERSITY OF NEBRASKA

PLEASE NOTE:

**Some pages may have
indistinct print.**

Filmed as received.

University Microfilms, A Xerox Education Company

ACKNOWLEDGEMENTS

I wish to express sincere appreciation to my mentor, Kenneth L. Barker, Ph.D., Associate Professor of Biochemistry and Research Associate Professor of Obstetrics and Gynecology, for his scientific, academic, and personal advice and assistance. He gave freely of his time and energy to assist me at all stages of my study in order that I might learn to ask a scientific question, design experiments to adequately answer the question, interpret the results accurately and report the work clearly. I especially want to thank Dr. Barker for allowing me the freedom necessary to integrate my family with my scientific endeavors.

I wish to acknowledge the financial support of the National Institute of General Medical Sciences of the National Institutes of Health who provided me with a predoctoral fellowship, GM 41,428.

I wish to thank my supervisory committee: Drs. Kenneth L. Barker, William R. Ruegamer, John F. Hofert, Theodore Mahowald and Norman G. Miller for their advice and constructive criticism during the course of these experiments and the writing of this dissertation.

I wish to thank Mrs. Joyce Meyers who typed the preliminary and final copies of this thesis.

A special note of thanks to my husband, Thomas M. O'Dorisio, M. D. who continually gave me support and encouragement to continue my scientific pursuits. In addition he served as dissertation illustrator and as babysitter.

TABLE OF CONTENTS

	Page
LIST OF FIGURES	vi
LIST OF TABLES	viii
NOTATION	ix
I. INTRODUCTION	1
II. LITERATURE REVIEW	3
A. Synthesis of NAD	3
1. Tryptophan Pathway	3
2. Glycerol-Aspartate Pathway	6
3. Acetate-Formate Pathway	6
4. Nicotinic Acid and Nicotinamide Pathways	7
B. NADP Synthesis	19
C. Control of NAD and NADP Levels	20
1. Control of Synthesis	20
2. Control of Pyridine Nucleotide Degradation	22
3. Effects of Drugs	24
4. Effects of Hormones on Pyridine Nucleotides	24
a. Liver	24
b. Thyroid	25
c. Ventral Prostate	26
d. Uterus	26
D. Control Mediated Via NAD and NADP	26
E. Separation and Identification of Pyridine Nucleotides and Synthetic Intermediates	29
1. Separation	29
2. Identification	32

F. Crossover Technique for Identification of Interaction Sites in a Reaction Sequence	33
III. METHODS AND MATERIALS	40
A. Animals	40
B. Separation and Identification	40
1. Ion Exchange Chromotography	40
2. Thin Layer Chromotography	44
3. Paper Chromotography	45
4. UV Spectra	45
5. Quantification	46
6. Counting	47
C. Synthesis of dNAD	47
D. Synthesis of dNMN	48
E. Preparation of Radioactive Intermediates	49
F. <u>In vitro</u> Experiments	51
1. Incubation and Homogenization	51
2. DNA Assays	52
3. Calculation of dpm/uterus for Each Nucleotide	53
G. Crossover Experiments	54
H. Enzyme Studies	55
1. Nuclei Preparation	55
2. Enzyme Assays	56
I. Materials	58
IV. RESULTS AND DISCUSSION	59
A. Preparation of dNAD	59
B. Preparation of dNMN	62

C. Separation of Intermediates	63
D. <u>In vitro</u> Incubation System	71
E. Effect of Precursor Concentration	73
F. Competition Experiments	83
G. Time Course of ^{14}C Incorporation	89
H. Effect of Estradiol on ^{14}C -Precursor Incorporation . . .	93
I. Effect of Estradiol on Time Course of ^{14}C -Nicotinic Acid Incorporation	96
J. Crossover Studies	102
K. Enzyme Studies	107
V. CONCLUSIONS	111
VI. BIBLIOGRAPHY	113

LIST OF FIGURES

	Page
Figure 1. Biosynthesis of NAD and NADP	4
Figure 2. Biosynthesis of NAD and NADP	8
Figure 3. Nucleotide Analyzing System	42
Figure 4. Identification and Purity of dNAD by Thin Layer Chromotography	60
Figure 5. Ultraviolet Absorption Spectra of dNAD	61
Figure 6. Identification and Purity of dNMN by Thin Layer Chromotography	64
Figure 7. Ultraviolet Absorption Spectra of dNMN	65
Figure 8. Pattern of nucleotide Elution from Dowex AG1-X8 Column	67
Figure 9. Separation and Identification of NAM and NMN by Thin Layer Chromotography	68
Figure 10. Identification and Purity of NAD and NAc by Thin Layer Chromotography	69
Figure 11. Identification and Purity of dNMN, dNAD and NADP by Thin Layer Chromotography	70
Figure 12. Effect of Precursor Concentration on the Rate of Incorporation of ^{14}C -Nicotinic Acid into NAD by Uterine Tissue Slices <u>in vitro</u>	75
Figure 13. Double-reciprocal Plot of the Effect of ^{14}C -Nicotinic Acid Concentration on the Rate of Incorporation of ^{14}C into NAD by Uterine Tissue Slices <u>in vitro</u>	76
Figure 14. Effect of Precursor Concentration on the Rate of Incorporation of ^{14}C -Nicotinamide into NAD by Uterine Tissue Slices <u>in vitro</u>	79
Figure 15. Double-reciprocal Plot of the Effect of ^{14}C -Nicotinamide Concentration on the Rate of Incorporation of ^{14}C into NAD by Uterine Tissue Slices <u>in vitro</u>	80

Figure 16.	Effect of Nicotinamide on the Rate of Incorporation of ^{14}C -Nicotinic Acid by Uterine Tissue Slices <u>in vitro</u>	85
Figure 17.	Effect of Nicotinic Acid on the Rate of Incorporation of ^{14}C -Nicotinamide into NAD by Uterine Tissue Slices <u>in vitro</u>	88
Figure 18.	Incorporation of ^{14}C -Nicotinic Acid into Intermediates of the NAD Biosynthetic Pathway by Uterine Tissue Slices <u>in vitro</u>	99
Figure 19.	Effect of Estradiol on Incorporation of ^{14}C - Nicotinic Acid into Intermediates of the NAD Bio- synthetic Pathways by Uterine Tissue Slices <u>in vitro</u> .	100
Figure 20.	Crossover Plot of Nicotinic Acid Pathway for NAD and NADP Synthesis	105
Figure 21.	Crossover Plot of Nicotinic Acid Pathway for NAD and NADP Synthesis	106

LIST OF TABLES

	Page
Table 1. Enzymes Involved in Biosynthesis of NAD and NADP: Characteristics and Kinetics	10
Table 2. Effect of Precursor Concentration on the Rate of Incorporation of ^{14}C -Nicotinic Acid into NAD by Uterine Tissue Slices <u>in vitro</u>	74
Table 3. Effect of Precursor Concentration on the Rate of Incorporation of ^{14}C -Nicotinamide into NAD by Uterine Tissue Slices <u>in vitro</u>	78
Table 4. Effect of Nicotinamide on the Rate of Incorporation of ^{14}C -Nicotinic Acid into NAD by Uterine Tissue Slices <u>in vitro</u>	84
Table 5. Effect of Nicotinic Acid on the Rate of Incorporation of ^{14}C -Nicotinamide into NAD by Uterine Tissue Slices <u>in vitro</u>	87
Table 6. Incorporation of ^{14}C -Nicotinamide and ^{14}C -Nicotinic Acid into Intermediates of the NAD Biosynthetic Pathways by Uterine Tissue Slices <u>in vitro</u>	90
Table 7. Effect of Estradiol on the Rate of Incorporation of ^{14}C -Nicotinamide and ^{14}C -Nicotinic Acid into Intermediates of the NAD Biosynthetic Pathways by Uterine Tissue Slices <u>in vitro</u>	95
Table 8. Effect of Estradiol on Incorporation of ^{14}C -Nicotinic Acid into Intermediates of the NAD Biosynthetic Pathways by Uterine Tissue Slices <u>in vitro</u>	97
Table 9. Effect of Estradiol on the Amount of Various Intermediates of the Nicotinic Acid Pathway for NAD Biosynthesis in the Uterus of the Ovariectomized Mature Rat	103
Table 10. Effect of Estradiol on the dNAD Pyrophosphorylase, NAD Pyrophosphorylase and NAD Kinase Activities in Rat Uterine Nuclei	108

NOTATION

A ₂₆₀	Absorbancy at 260 mμ
ADH	Yeast Alcohol Dehydrogenase
ADP	Adenosine Diphosphate
ADPR	Adenosine Diphosphate Ribose
AMP	Adenosine Monophosphate
ATP	Adenosine Triphosphate
cpm	counts per minute
dNAD	deamido Nicotinamide Adenine Dinucleotide
dNMN	Nicotinic Acid Mononucleotide
dpm	disintegrations per minute
E ₂	Estradiol-17β
Estrogen	Estradiol-17β
Estradiol	Estradiol-17β
fp	Flavoprotein
G6PDH	Glucose-6-Phosphate Dehydrogenase
NAc	Nicotinic Acid
NAD	Nicotinamide Adenine Dinucleotide
NADH	Reduced Nicotinamide Adenine Dinucleotide
NADP	Nicotinamide Adenine Dinucleotide Phosphate
NADPH	Reduced Nicotinamide Adenine Dinucleotide Phosphate
NAm	Nicotinamide
NMN	Nicotinamide Mononucleotide
PCA	Perchloric Acid
PRPP	Phosphoribosyl Pyrophosphate
UV	Ultraviolet

INTRODUCTION

The pyridine nucleotides NAD, NADH, NADP and NADPH are best known for their role as coenzymes in dehydrogenase enzyme reactions. They serve as cofactors for a variety of cytoplasmic enzymes, including enzymes catalyzing key steps in glycolysis and pentose metabolism, but they have important functions in other cellular compartments as well.

NAD is a substrate for the nuclear enzyme, NAD glycohydrolase, which releases nicotinamide and polymerizes ADP-ribose moieties, linking ADP ribose covalently to the histones associated with nuclear chromatin. Thus, nuclear pyridine nucleotides may participate in regulation of DNA synthesis. NAD serves as an AMP donor for the DNA ligase reaction in E. coli and as such participates directly in DNA synthesis and repair. NADH, and NADPH via transhydrogenase, are electron donors for oxidative phosphorylation. Hence, pyridine nucleotides, by their abundance or lack, may control the mitochondrial formation of ATP. Reduced nucleotides donate hydrogen for fatty acid synthesis in cytoplasm and in mitochondria and for steroid synthesis in mitochondria and in microsomes. Again, metabolism may be regulated by the availability of pyridine nucleotides. These nucleotides can also activate or inhibit enzymes by either competitive or allosteric mechanisms.

No other nucleotide can assume such varied roles as substrate, coenzyme, electron donor, activator and inhibitor and can function

in nucleus, cytoplasm, mitochondria and microsomes. Because of the ubiquitous and versatile nature of the pyridine nucleotides, control of cellular metabolism may conceivably be mediated through changes in the levels, oxidative states or cellular distribution of NAD and NADP.

The specific aims of the research to be reported in this dissertation were as follows:

- 1) To determine whether estrogen-induced increases in uterine NAD and NADP are the result of an increased rate of de novo synthesis of these coenzymes.
- 2) To determine which pathway or pathways for biosynthesis of NAD and NADP are active in the uterus.
- 3) To determine which metabolic step(s) in the biosynthesis of NAD and NADP in the uterus are increased in response to administration in vivo of estradiol.

LITERATURE REVIEW

Synthesis of NAD


The principal precursors for the biosynthesis of NAD and NADP are tryptophan, glycerol-aspartate, acetate-formate, nicotinamide and nicotinic acid (Fig. 1).

Tryptophan Pathway

It was known as early as 1945 (Krehl et al.) that tryptophan was an adequate dietary substitute for niacin in rats. Nishizuka and Hayaishi (1963) demonstrated the presence of a pathway by which tryptophan can ultimately be converted to the niacin portion of NAD. Tryptophan oxygenase (L-Tryptophan oxygen oxidoreductase EC 1.13.1.12) converts tryptophan to N-formyl kynurenine by splitting the ring and adding H_2O . Enzymatic removal of a CO group results in formation of kynurenine to which a hydroxyl is added to form 3-OH-kynurenine. Alanine is split out resulting in 3-OH-anthranilic acid and the ring is opened to give α -amino- β -carboxymuconic ϵ -semialdehyde.

This product has two possible fates. It may spontaneously lose H_2O and cyclize to form quinolinic acid or it may be used as a substrate by picolinic carboxylase for formation of α -aminomuconic- ϵ -semialdehyde, a Coenzyme A precursor. Thus NAD synthesis from tryptophan is inversely related to picolinic carboxylase activity. When carboxylase activity decreases, as in diabetes, NAD synthesis from tryptophan increases (Mehler et al., 1958). Picolinic

FIGURE 1.
Biosynthesis of NAD and NADP



- The enzymes which catalyze the reactions depicted above are:
- | | |
|----------------------------------|------------------------------------|
| 1. Tryptophan Oxygenase | 9. dNAD Pyrophosphorylase |
| 2. Kynurenine Formylase | 10. NAD Synthetase |
| 3. Kynurenine-3-hydroxylase | 11. Nicotinamide Deamidase |
| 4. Kynurenine hydrolase | 12. NAc Phosphoribosyl Transferase |
| 5. 3-OH-anthranilic acid Oxidase | 13. NAM Phosphoribosyl Transferase |
| 6. Spontaneous | 14. NAD Pyrophosphorylase |
| 7. Quinolinate Transribosylase | 15. Unknown enzymes |
| 8. Quinolinate Transribosylase | 16. NAD Kinase |

carboxylase activity is very high in cat liver. In this animal, tryptophan cannot fulfill the requirement for niacin. Since all of the α -amino- β -carboxymuconic- ϵ -semialdehyde formed from tryptophan is converted to α -aminomuconic- ϵ -semialdehyde and ultimately to Coenzyme A, no NAD can be synthesized from tryptophan (Nishizuka and Hayaishi, 1971 and Henderson and Swan, 1971).

When picolinic carboxylase activity is low, the quinolinic acid formed is converted to nicotinic acid ribonucleoside and then to nicotinic acid mononucleotide, deamido NAD and NAD. Thus, the tryptophan pathway has two possible regulatory steps, those catalyzed by tryptophan oxygenase and by picolinic acid carboxylase. Partridge et al., (1952) reported the conversion of tryptophan to niacin in the rat, but Nishizuka and Hayaishi (1963) established conclusively that niacin is not a free intermediate in the tryptophan pathway. McDonald et al., (1968) presented the metabolic steps in the conversion of tryptophan to nicotinic acid mononucleotide. This sequence of reactions is also given in Fig. 1.

The tryptophan pathway is operative in mouse liver (McDonald et al., 1968) but tumors from these animals are unable to utilize tryptophan for NAD synthesis. Apparently, the tumors are unable to decarboxylate quinolinic acid. The ability to synthesize NAD from tryptophan is not seen in chick embryos until the sixth day (Shimayama et al., 1969). The tryptophan pathway is operative in mammals and in *Neurospora*, but only one bacterial species, *Xanthomonas pruni* is known to possess the necessary enzymes (Saxton et al.,

Glycerol-Aspartate Pathway

Higher plants and many microorganisms synthesize quinolinic acid from glycerol and aspartate. Since quinolinic acid can be converted to dNMN, the condensation of glycerol and aspartic acid is considered a de novo pathway for NAD synthesis (Rowen and Kornberg, 1951). The sequence of reactions by which quinolinic acid is formed from glycerol and aspartate is unknown. Chandler et al., (1970) postulated that a direct condensation occurs but have no evidence yet as to whether the nitrogen-carbon bond or carbon-carbon bond is formed first. Saxton and coworkers (1969) found this pathway to be operative in E. coli, B. subtilis and B. megaterium. They found the pathway to be inhibited when the bacteria were grown in medium containing high levels of nicotinic acid.

Acetate-Formate Pathway

In Clostridium butylicum, acetate and formate are combined with aspartate to form quinolinic acid which then enters the nicotinic acid synthetic pathway at the nicotinic acid mononucleotide step (Isquith and Moat, 1966).

Because quinolinic acid (derived from any of these three sources) is an intermediate of NAD biosynthesis in mammalian tissue and bacteria, many studies of NAD biosynthesis have been done using labeled quinolinic acid. From these studies it is generally concluded that these three pathways (tryptophan, glycerol-aspartate or acetate-formate) are relatively inactive in all organisms unless there is a deficiency

of nicotinic acid and nicotinamide (Chaykin, 1967). While this conclusion is probably valid the interpretation of studies using labeled quinolinic acid as a precursor may be biased due to the relatively poor penetration of this compound into liver cells (Ijichi et al., 1966).


Nicotinic Acid and Nicotinamide Pathways

Nicotinamide and nicotinic acid can serve as NAD precursors in almost all mammalian tissues. Prior to the isolation and determination of the structure of NAD it was shown that administration of nicotinic acid to humans, both normal and pellagrins, caused an increase in blood levels of "V factor" (Kahn, 1938; Hoagland and Ward, 1942; Hoagland et al., 1943; Handler and Kahn, 1943). A smaller increase in "V factor" levels could be effected by administration of nicotinamide but the increase was always less than the increase caused by nicotinic acid (Hoagland et al., 1943 and Handler and Kahn, 1943). "V factor" was later shown to be primarily NAD.

A major discovery was made by Priess and Handler (1958a). They isolated two new compounds thought to be intermediates in NAD biosynthesis and identified them as nicotinic acid mononucleotide (dNMN) and nicotinic acid dinucleotide (dNAD). They were able to demonstrate the presence in human erythrocytes of all the enzymes necessary for the direct synthesis of NAD from nicotinic acid (see Fig. 2). The sequence in the Preiss-Handler pathway for NAD synthesis

FIGURE 2.

Biosynthesis of NAD and NADP




The enzymes for the Nicotinamide Pathway are:

1. Nicotinamide Phosphoribosyl Transferase
2. NAD Pyrophosphorylase


The enzymes for the Nicotinic Acid Pathway are:

3. Nicotinic Acid Phosphoribosyl Transferase
4. dNAD Pyrophosphorylase
5. NAD Synthetase
6. NAD Kinase

was defined as:



They also found an enzyme capable of converting nicotinamide to NMN and proposed a second sequence for the synthesis of NAD from nicotinamide as follows:



Nicotinamide: pyrophosphate phosphoribosyltransferase

(EC 2.4.2.12 and Reaction 4) has a very high K_m for nicotinamide and the activity of the next enzyme, (ATP: NMN adenylyltransferase EC 2.7.7.1), is very low in human erythrocytes (Table I). This observation, coupled with the earlier observations that nicotinic acid was a better NAD precursor than nicotinamide, led Preiss and Handler to postulate that the nicotinic acid pathway was the pre-dominant route for NAD synthesis in mammalian tissues.

The relative efficacy of nicotinamide versus nicotinic acid as NAD precursor and the relative importance of each pathway was a subject of controversy for 15 years.

Table 1. Enzymes Involved in Biosynthesis of NAD and NADP: Characteristics and Kinetics.

Enzyme ^a	Reaction	Organism, Cell Location	K _m	pH opt	Inhibitors and Activators	Isolation Purification
Nicotinamide: pyrophosphate phosphoribosyl transferase - EC 2.4.2.12 (NMN pyrophos- phorylase)	NAm + PRPP + ATP → NMN + ADP + PP + P _i	Lacto bacillus fructosus cell supernatant Rat liver cytoplasmic (acid soluble)	NAm 2x10 ⁻⁶ M PRPP 4x10 ⁻⁵ M ATP 6.7x10 ⁻⁴ M	6-7 8.0	<u>Inhibitors</u> NMN NAD Unknown endogenous NAM analogues <u>Activators</u> Mg ⁺⁺ ATP	Ohtsu et al., 1967 Dietrich et al., 1966
ATP: NMN Adenyl- transferase - EC 2.7.7.1 (NAD pyrophos- phorylase)	NMN + ATP → NAD + PP rat liver nuclei	Lactobacillus fructosus protamine SO ₄ precipitate of acid super- natant	NMN 6.7x10 ⁻⁴ M 2.7x10 ⁻³ M ATP		<u>Inhibitors</u> hypophysectomy adrenalectomy <u>Activators</u> α-amanatin	Ohtsu et al., 1967 Strip and Corte 1968 Traub et al., 1968

(continued next page)

Table 1. (continued)

Enzyme ^a	Reaction	Organism, Cell Location	K _m	pH opt	Inhibitors and Activators	Isolation Purification
Nicotinate: pyrophosphate phosphoribosyl transferase - EC 2.4.2.11 (Nicotinic acid phosphoribosyl- transferase)	NAC + PRPP + ATP → dNMN + PP + ADP	Baker's yeast acid supernatant	NAC 1.85x 10 ⁻⁶ M ATP 1.2x10 ⁻⁴ M PRPP 7.7x10 ⁻⁶ M	8.0	<u>Inhibitors</u> ADP dNMN hypoxanthine NaF <u>Activators</u> Mg ⁺⁺ ATP	Honjo, 1971
ATP: dNMN adenylyl- transferase - EC 2.7.7.18 (dNAD pyrophos- phorylase)	dNMN + ATP → dNAD + PP _i	Hog liver acid supernatant E. coli acid soluble	dNMN 3x10 ⁻⁵ M ATP 5x10 ⁻⁴ M	7.5	<u>Inhibitors</u> None tested <u>Activators</u> Mg ⁺⁺	Preiss and Handler, 1958 Imlande, 1961

(continued next page)